{"id":12756,"date":"2019-04-10T11:48:04","date_gmt":"2019-04-10T09:48:04","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=12756"},"modified":"2019-04-16T11:51:10","modified_gmt":"2019-04-16T09:51:10","slug":"synaffix-announces-125m-license-agreement-with-shanghai-miracogen","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/","title":{"rendered":"Synaffix Announces $125m License Agreement with Shanghai Miracogen"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Synaffix, a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered into a license agreement with Shanghai Miracogen Inc., a Chinese biotechnology company with a clinical-stage pipeline of ADCs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Under the terms of the agreement, Miracogen has been granted non-exclusive rights to Synaffix\u2019s proprietary&nbsp; GlycoConnect\u2122 and HydraSpace\u2122 ADC technologies for use in its next clinical candidate. Synaffix is eligible to receive upfront and potential milestone payments that total $125 million, plus royalties\u00ad\u00ad.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Miracogen will be responsible for the research, development, manufacturing and commercial-ization of the ADC product while Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary GlycoConnect\u2122 and HydraSpace\u2122 technologies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This agreement follows a research collaboration between the two companies which was centered around a specific drug candidate that has now been selected for clinical development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mary Hu, Chairman and CEO of Miracogen, said:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cWe are very pleased to have reached this license agreement with Synaffix. We believe that their GlycoConnect\u2122 and HydraSpace\u2122 technologies will further differentiate our pipeline of ADCs by delivering valuable expansion of the therapeutic index. Our efficient and collaborative relationship during the research phase has provided us with a highly competitive new asset for the Miracogen pipeline in just a five-month timeframe. We look forward to continuing our collaboration as we advance this candidate into the clinic and beyond to benefit cancer patients.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Peter van de Sande, CEO of Synaffix, said:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cWorking with Miracogen has been a rewarding experience. As we transition into the development phase together, this license agreement with Miracogen provides additional validation of our GlycoConnect\u2122 and HydraSpace\u2122 technologies.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThere is a clear trend in China towards developing innovative products and as such, ADCs have emerged as a strong area of growth within the field of oncology. Our proprietary technologies can address the current unmet need for clinical candidates with an enhanced therapeutic index, thereby driving further growth of our activities in China and other markets.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source: <a href=\"http:\/\/www.synaffix.com\/news\/synaffix-commands-ip-space-glycan-conjugated-adcs-major-expansion-granted-patent-portfolio-2-3-2-2\/\"><strong>Synaffix<\/strong><\/a><br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Synaffix, a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered into a license agreement with Shanghai Miracogen Inc., a Chinese biotechnology company with a clinical-stage pipeline of ADCs. Under the terms of the agreement, Miracogen has been [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39,43],"tags":[],"class_list":["post-12756","post","type-post","status-publish","format-standard","hentry","category-gezondheid","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Synaffix Announces $125m License Agreement with Shanghai Miracogen - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Synaffix Announces $125m License Agreement with Shanghai Miracogen - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Synaffix, a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered into a license agreement with Shanghai Miracogen Inc., a Chinese biotechnology company with a clinical-stage pipeline of ADCs. Under the terms of the agreement, Miracogen has been [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-10T09:48:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-04-16T09:51:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Synaffix Announces $125m License Agreement with Shanghai Miracogen\",\"datePublished\":\"2019-04-10T09:48:04+00:00\",\"dateModified\":\"2019-04-16T09:51:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\\\/\"},\"wordCount\":348,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\",\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\\\/\",\"name\":\"Synaffix Announces $125m License Agreement with Shanghai Miracogen - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2019-04-10T09:48:04+00:00\",\"dateModified\":\"2019-04-16T09:51:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Synaffix Announces $125m License Agreement with Shanghai Miracogen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Synaffix Announces $125m License Agreement with Shanghai Miracogen - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/","og_locale":"en_US","og_type":"article","og_title":"Synaffix Announces $125m License Agreement with Shanghai Miracogen - hollandbio","og_description":"Synaffix, a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered into a license agreement with Shanghai Miracogen Inc., a Chinese biotechnology company with a clinical-stage pipeline of ADCs. Under the terms of the agreement, Miracogen has been [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/","og_site_name":"hollandbio","article_published_time":"2019-04-10T09:48:04+00:00","article_modified_time":"2019-04-16T09:51:10+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Synaffix Announces $125m License Agreement with Shanghai Miracogen","datePublished":"2019-04-10T09:48:04+00:00","dateModified":"2019-04-16T09:51:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/"},"wordCount":348,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid","Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/","name":"Synaffix Announces $125m License Agreement with Shanghai Miracogen - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2019-04-10T09:48:04+00:00","dateModified":"2019-04-16T09:51:10+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/synaffix-announces-125m-license-agreement-with-shanghai-miracogen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Synaffix Announces $125m License Agreement with Shanghai Miracogen"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/12756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=12756"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/12756\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=12756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=12756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=12756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}